Topics

Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement

13:14 EDT 1 May 2019 | SCRIP

Although Samsung has not provided 180-day advance notice of commercialization for Eticovo, its recently approved biosimilar to Enbrel, Amgen seeks...

      

Related Stories

 

Original Article: Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement

NEXT ARTICLE

More From BioPortfolio on "Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement"

Quick Search

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...